Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

As with many early-stage companies, Vaccinex funnelled the majority of its resources into a lead candidate. The asset, called ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

The Ironman Triathlon is a grueling 140 miles, which includes a 2.4-mile swim, a 112-mile bike ride and a 26.2-mile marathon ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...